Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TRISHA WISE-DRAPER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1306162367
CMS profile
1348174
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,500.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,500.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $1,500.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TRISHA WISE-DRAPER

NPI 1306162367 · CMS profile ID 1348174

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306162367?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306162367?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306162367?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1306162367?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $1,500.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $1,500.0010/13/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848310327 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $262.13 3
PY2020 $590.34 6
PY2021 $1,500.00 1
PY2023 $7,777.55 11
PY2024 $14,141.99 15
PY2025 $19,550.73 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,091,344.57 191
PY2024 Recipient $1,142.00 1
PY2024 Principal investigator $1,113,643.03 103
PY2023 Principal investigator $647,553.50 123
PY2022 Principal investigator $951,903.86 101
PY2021 Principal investigator $1,602,672.00 113
PY2020 Recipient $2,270.00 3
PY2020 Principal investigator $2,351,551.68 45
PY2019 Principal investigator $1,957,016.08 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

104 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ares Trading SA $1,008.00 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562736
Principal investigator 1 Ares Trading SA $948.00 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562740
Principal investigator 1 Ares Trading SA $734.40 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562749
Principal investigator 1 Ares Trading SA $1,008.00 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562755
Principal investigator 1 Ares Trading SA $1,008.00 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562767
Principal investigator 1 Ares Trading SA $1,008.00 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562773
Principal investigator 1 Ares Trading SA $948.00 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562793
Principal investigator 1 Ares Trading SA $948.00 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562807
Principal investigator 1 Ares Trading SA $948.00 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562812
Principal investigator 1 Ares Trading SA $948.00 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562821
Principal investigator 1 Ares Trading SA $948.00 12/20/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562828
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $22,401.00 12/09/2024 Non-covered Recipient Entity
University Of Cincinnati
Phase I/II FIH Monotherapy/Nivo Combination No dispute reported 06/30/2026 1123480676
Principal investigator 1 Janssen Research & Development, LLC $251,455.90 12/02/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
Phase II study to evaluate amivantamab in recurrent and metastatic adenoid cystic carcinoma No dispute reported 06/30/2026 1078999276
Principal investigator 1 Ares Trading SA $948.00 11/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562715
Principal investigator 1 Ares Trading SA $948.00 11/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562719
Principal investigator 1 Ares Trading SA $1,008.00 11/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562727
Principal investigator 1 Ares Trading SA $272.40 11/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562752
Principal investigator 1 Ares Trading SA $948.00 11/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562782
Principal investigator 1 Ares Trading SA $948.00 11/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562790
Principal investigator 1 Ares Trading SA $1,008.00 11/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562837
Principal investigator 1 Daiichi Sankyo Company LTD $50,198.00 10/08/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1075870271
Recipient Eli Lilly and Company $1,142.00 09/24/2024 Covered Recipient Physician A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 1137349789
Principal investigator 1 Coherus Biosciences Inc. $51,382.00 09/20/2024 Non-covered Recipient Entity
University of Cincinnati
SRF114-101 No dispute reported 06/30/2026 1147273463
Principal investigator 1 Ares Trading SA $597.60 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563046
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563060
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563067
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563076
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563084
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563088
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563095
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563100
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563111
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563115
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563120
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563124
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563135
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563142
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563151
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563155
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563164
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563174
Principal investigator 1 Ares Trading SA $948.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563181
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563188
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563190
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563192
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563194
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563196
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563198
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563204
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563213
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563225
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563234
Principal investigator 1 Ares Trading SA $1,008.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563238
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 09/09/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074140
Principal investigator 1 Daiichi Sankyo Company LTD $4,725.00 09/06/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1075870273
Principal investigator 1 Daiichi Sankyo Inc. $500.00 09/03/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074132
Principal investigator 1 Daiichi Sankyo Inc. $2,430.00 09/03/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074134
Principal investigator 1 Daiichi Sankyo Inc. $4,860.00 09/03/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074136
Principal investigator 1 Daiichi Sankyo Inc. $16,000.00 09/03/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074138
Principal investigator 1 Daiichi Sankyo Company LTD $23,790.00 09/02/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1075870269
Principal investigator 1 Daiichi Sankyo Inc. $675.00 08/01/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074120
Principal investigator 1 Daiichi Sankyo Inc. $945.00 08/01/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074122
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 08/01/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074124
Principal investigator 1 Daiichi Sankyo Inc. $2,700.00 08/01/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074126
Principal investigator 1 Daiichi Sankyo Inc. $2,700.00 08/01/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074128
Principal investigator 1 Daiichi Sankyo Inc. $13,500.00 08/01/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1086074130
Principal investigator 1 Daiichi Sankyo Company LTD $23,020.00 07/30/2024 Non-covered Recipient Entity
University Of Cincinnati
DS1055-A-J101 No dispute reported 06/30/2026 1075870267
Principal investigator 1 Ares Trading SA $719.10 07/05/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563052
Principal investigator 1 Janssen Research & Development, LLC $184,804.87 06/24/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
Phase II study to evaluate amivantamab in recurrent and metastatic adenoid cystic carcinoma No dispute reported 06/30/2026 1078999274
Principal investigator 1 PFIZER INC. $5,873.00 06/05/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER
A PHASE 1 STUDY OF SGNTGT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1130963384
Principal investigator 1 Ares Trading SA $1,008.00 04/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562988
Principal investigator 1 Ares Trading SA $1,008.00 04/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563008
Principal investigator 1 Ares Trading SA $948.00 04/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563014
Principal investigator 1 Ares Trading SA $948.00 04/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563019
Principal investigator 1 Ares Trading SA $948.00 04/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563030
Principal investigator 1 Ares Trading SA $367.20 04/25/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133563043
Principal investigator 1 Eli Lilly and Company $201.25 04/25/2024 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 1137349291
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61,175.63 04/22/2024 Non-covered Recipient Entity
University Of Cincinnati
2016-NIV-0647 Phase II investigation of adjuvant nivolumab after salvage resection in pts treated with definitive chemotherapy and radiation No dispute reported 06/30/2026 1123480668
Principal investigator 1 Genentech, Inc. $1,000.00 03/19/2024 Non-covered Recipient Entity
UC HEALTH LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1133461203
Principal investigator 1 Genentech, Inc. $6,000.00 03/19/2024 Non-covered Recipient Entity
UC HEALTH LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1133461207
Principal investigator 1 Ares Trading SA $948.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562841
Principal investigator 1 Ares Trading SA $948.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562847
Principal investigator 1 Ares Trading SA $948.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562879
Principal investigator 1 Ares Trading SA $948.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562885
Principal investigator 1 Ares Trading SA $948.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562889
Principal investigator 1 Ares Trading SA $948.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562892
Principal investigator 1 Ares Trading SA $948.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562899
Principal investigator 1 Ares Trading SA $1,008.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562910
Principal investigator 1 Ares Trading SA $1,008.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562919
Principal investigator 1 Ares Trading SA $813.60 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562924
Principal investigator 1 Ares Trading SA $1,008.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562948
Principal investigator 1 Ares Trading SA $1,008.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562954
Principal investigator 1 Ares Trading SA $1,008.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562958
Principal investigator 1 Ares Trading SA $1,008.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562974
Principal investigator 1 Ares Trading SA $948.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562979
Principal investigator 1 Ares Trading SA $948.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562982
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $144,083.28 02/27/2024 Non-covered Recipient Entity
University Of Cincinnati
PhI/II TIGIT BiSpec combo (Nivo/NG CTLA4) safety & NSCLC expansion - A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer No dispute reported 06/30/2026 1123480682
Principal investigator 1 Eli Lilly and Company $25,584.00 02/13/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 1137368746
Principal investigator 1 AstraZeneca Pharmaceuticals LP $115,144.00 02/08/2024 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-label, Phase II Study of Durvalumab (MEDI4736) in combination with Cetuximab in Previously Treated Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1110835855
Principal investigator 1 AstraZeneca UK Limited $21,125.00 01/29/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
A Phase 1b 2 Open Label Multicentre Study Assessing the Safety Tolerability Pharmacokinetics and Preliminary Anti tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1110844320
Principal investigator 1 Ares Trading SA $948.00 01/03/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562852
Principal investigator 1 Ares Trading SA $556.80 01/03/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562869
Principal investigator 1 Ares Trading SA $1,008.00 01/03/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562929
Principal investigator 1 Ares Trading SA $1,008.00 01/03/2024 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1133562942